[Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
This review summarizes data on the main approaches used for the search of biologically active compounds modulating the level and physiological activity of incretins. Currently two groups of drugs are used in clinical practice: they either replenish the deficit of incretins (glucagon-like peptide-1 receptor agonists) or inhibit the degradation processes (dipeptidyl peptidase 4 inhibitors). In addition, new groups of substances are actively searched. These include non-peptide agonists of glucagon-like peptide-1 receptors, agonists/antagonists of glucose-dependent insulinotropic peptide, the hybrid polypeptides based on glucagon-like peptide-1 and glucagon.
Volgograd State Medical University, Volgograd, Russia.
A A
AA
Spasov
Volgograd State Medical University, Volgograd, Russia.
N I
NI
Chepljaeva
D000595:Amino Acid Sequence; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018819:Dipeptidyl Peptidase 4 / Q000235:genetics / Q000378:metabolism; D055808:Drug Discovery; D005749:Gastric Inhibitory Polypeptide / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation; D005934:Glucagon / Q000737:chemistry / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000235:genetics / Q000378:metabolism; D000067757:Glucagon-Like Peptide-1 Receptor / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D008969:Molecular Sequence Data; D057786:Peptidomimetics / Q000737:chemistry / Q000627:therapeutic use*; D015398:Signal Transduction; D054852:Small Molecule Libraries / Q000737:chemistry / Q000627:therapeutic use*; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D057786:Peptidomimetics; D054852:Small Molecule Libraries; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
dipeptidyl peptidase 4; glucagon-like peptide-1; glucose-dependent insulinotropic peptide; incretin; type 2 diabetes mellitus